Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Outlook

Thelansis’s “Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Overview

Non-metastatic castration-sensitive prostate cancer (nmCSPC) constitutes a transient stage of the disease. It emerges with resistance to castration (manifested by testosterone levels falling below 50 ng/mL) after androgen deprivation therapy (ADT). The absence of observable metastases in standard imaging scans characterizes this stage. Simultaneously, there is a gradual increase in prostate-specific antigen (PSA) levels, reaching a minimum of 25% higher than the lowest point (nadir) while starting with a PSA level of ≥ 1.0 ng/mL. This increase must be at least 2 ng/mL and verified by a second reading. Nevertheless, the progression of this condition into metastatic disease is a complex process that is not yet fully comprehended. Most individuals diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC) do not exhibit symptoms or experience only minor ones due to localized treatment effects. In cases where the PSA doubling time is short (< 10 months) and initial PSA levels are high, the likelihood of bone metastases is notably elevated. These metastases are subsequently linked to prostate cancer. Various imaging methods are regularly employed to determine prostate cancer extent and identify metastasis and tumor recurrence signs. The advancement from non-metastatic castration-resistant prostate cancer to metastatic disease typically involves the lymph nodes and bones. Around thirty percent of patients are anticipated to develop bone metastases within 2 years. The most frequently affected areas are the pelvis, spine, and ribs. The current strategies for treating additional hormonal therapy in non-metastatic castration-resistant prostate cancer focus on hindering androgen production or its effects. The guidelines from esteemed medical organizations, such as the NCCN and EAU, now suggest that patients with nonmetastatic castration-resistant prostate cancer and a PSA doubling time of ≤ 10 months who are at an escalated risk of disease progression should receive treatments like enzalutamide, apalutamide, or darolutamide. These treatments are administered alongside ongoing ADT to delay the onset of metastasis.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources &amp; assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034